2026年1月底,帕洛马行政主管出售了几十万股股票,尽管收入丰厚,股票不断上涨。 In late January 2026, Palomar executives sold hundreds of thousands in shares despite strong earnings and rising stock.

2026年1月底,包括首席执行官、首席执行官、首席执行官、总裁、首席执行官和其他内部人士在内的多位Palomar(PLMR)执行官出售了共计数十万美元收益的股票。 In late January 2026, multiple Palomar (PLMR) executives, including the CEO, CFO, president, COO, and other insiders, sold shares totaling hundreds of thousands of dollars in proceeds. 在证交会申报中披露的这些交易减少了其股份的低数字百分比。 The transactions, disclosed in SEC filings, reduced their stakes by low-single-digit percentages. 尽管内部出售,但Palomar报告,在2025年11月6日,Q4收入强劲,EPS为201美元,收入2.4466亿美元,超过估计。 Despite the insider selling, Palomar reported strong Q4 earnings on November 6, 2025, with $2.01 EPS and $244.66 million in revenue, surpassing estimates. 2月3日,库存以124.22美元关闭,增加了0.63美元,交易额超过平均数。 The stock closed at $124.22 on February 3, up $0.63, with trading volume above average. 分析师维持“机动购买”共识评级,目标为159.50美元,一些公司在2026年初更新了股票。 Analysts maintain a "Moderate Buy" consensus rating with a $159.50 target, and several firms upgraded the stock in early 2026. 该公司是一家专业保险控股公司,侧重于医疗中转损失和方案管理,拥有32.9亿美元的市场上限和90.25%的机构所有权。 The company, a specialty insurance holding firm focused on medical stop-loss and program management, has a $3.29 billion market cap and 90.25% institutional ownership.